Drugs / PEG-IFN-a2b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00573378 | Sep 2007 → Oct 2010 | chronic myeloid leukemia | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00630058 Background | Apr 2008 → Mar 2009 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IFN-a-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630058 ↗ |
| Modality | Protein / enzyme biologic | “pegylated interferon α-2b” NCT00573378 ↗ |
| Route | Subcutaneous | “150 µg subcutaneously” NCT00573378 ↗ |